[{"address1": "2617 Bissonnet Street", "address2": "Suite 233", "city": "Houston", "state": "TX", "zip": "77005", "country": "United States", "phone": "346 355 4099", "website": "https://www.alaunos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ferdinand  Groenewald", "age": 41, "title": "Vice President of Finance", "yearBorn": 1984, "fiscalYear": 2024, "totalPay": 159217, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 3, "overallRisk": 9, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.ziopharm.com/index.cfm", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.71, "open": 2.78, "dayLow": 2.6, "dayHigh": 2.78, "regularMarketPreviousClose": 2.71, "regularMarketOpen": 2.78, "regularMarketDayLow": 2.6, "regularMarketDayHigh": 2.78, "payoutRatio": 0.0, "beta": -1.276, "forwardPE": -4.383333, "volume": 36568, "regularMarketVolume": 36568, "averageVolume": 48213, "averageVolume10days": 15810, "averageDailyVolume10Day": 15810, "bid": 2.26, "ask": 3.22, "bidSize": 1, "askSize": 1, "marketCap": 5869710, "fiftyTwoWeekLow": 1.31, "fiftyTwoWeekHigh": 6.2, "allTimeHigh": 2400.0, "allTimeLow": 1.31, "priceToSalesTrailing12Months": 978.285, "fiftyDayAverage": 3.3658, "twoHundredDayAverage": 3.0354, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3931710, "profitMargins": 0.0, "floatShares": 1740291, "sharesOutstanding": 2231829, "sharesShort": 52250, "sharesShortPriorMonth": 44297, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0234, "heldPercentInsiders": 0.043720003, "heldPercentInstitutions": 0.04828, "shortRatio": 1.03, "shortPercentOfFloat": 0.024400001, "impliedSharesOutstanding": 2231829, "bookValue": 1.271, "priceToBook": 2.0692368, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -4025000, "trailingEps": -2.3, "forwardEps": -0.6, "lastSplitFactor": "1:10", "lastSplitDate": 1721260800, "enterpriseToRevenue": 655.285, "enterpriseToEbitda": -0.965, "52WeekChange": 0.7302631, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 2.63, "recommendationKey": "none", "totalCash": 1938000, "totalCashPerShare": 0.868, "ebitda": -4072500, "totalDebt": 0, "quickRatio": 2.104, "currentRatio": 2.915, "totalRevenue": 6000, "revenuePerShare": 0.003, "returnOnAssets": -0.69991994, "returnOnEquity": -1.45649, "grossProfits": -910000, "freeCashflow": -794625, "operatingCashflow": -2909000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -678.8334, "financialCurrency": "USD", "symbol": "TCRT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestampStart": 1755201600, "earningsTimestampEnd": 1755201600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.3, "epsForward": -0.6, "fiftyDayAverageChange": -0.7357998, "fiftyDayAverageChangePercent": -0.21861067, "twoHundredDayAverageChange": -0.4053998, "twoHundredDayAverageChangePercent": -0.13355729, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "ZIOPHARM Oncology, Inc.", "nameChangeDate": "2026-01-30", "regularMarketChangePercent": -2.9520266, "regularMarketPrice": 2.63, "postMarketTime": 1769812395, "regularMarketTime": 1769806802, "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "exchange": "NCM", "messageBoardId": "finmb_11686323", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1124890200000, "postMarketChangePercent": 4.9429607, "postMarketPrice": 2.76, "postMarketChange": 0.12999988, "regularMarketChange": -0.07999992, "regularMarketDayRange": "2.6 - 2.78", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 48213, "fiftyTwoWeekLowChange": 1.3200002, "fiftyTwoWeekLowChangePercent": 1.0076338, "fiftyTwoWeekRange": "1.31 - 6.2", "fiftyTwoWeekHighChange": -3.5699997, "fiftyTwoWeekHighChangePercent": -0.57580644, "fiftyTwoWeekChangePercent": 73.02631, "marketState": "CLOSED", "shortName": "Alaunos Therapeutics, Inc.", "longName": "Alaunos Therapeutics, Inc.", "corporateActions": [], "cryptoTradeable": false, "displayName": "Alaunos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]